Dr. Meghana Raghavendra
Claim this profileFranciscan Health Indianapolis
Studies Colorectal Cancer
Studies Adenocarcinoma
12 reported clinical trials
28 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
BRAF negative
2Adenocarcinoma
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Meghana Raghavendra is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Chemotherapy + Bevacizumab + Atezolizumab
for Colorectal Cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
More about Meghana Raghavendra
Clinical Trial Related5 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Meghana Raghavendra has experience with
- Fluorouracil
- Nivolumab
- Leucovorin Calcium
- Irinotecan Hydrochloride
- Bevacizumab
- Ipilimumab
Breakdown of trials Meghana Raghavendra has run
Colorectal Cancer
Adenocarcinoma
Colon Cancer
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Meghana Raghavendra specialize in?
Meghana Raghavendra focuses on Colorectal Cancer and Adenocarcinoma. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Meghana Raghavendra currently recruiting for clinical trials?
Yes, Meghana Raghavendra is currently recruiting for 2 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Meghana Raghavendra has studied deeply?
Yes, Meghana Raghavendra has studied treatments such as Fluorouracil, Nivolumab, Leucovorin Calcium.
What is the best way to schedule an appointment with Meghana Raghavendra?
Apply for one of the trials that Meghana Raghavendra is conducting.
What is the office address of Meghana Raghavendra?
The office of Meghana Raghavendra is located at: Franciscan Health Indianapolis, Indianapolis, Indiana 46237 United States. This is the address for their practice at the Franciscan Health Indianapolis.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.